Neuromodulation in Intractable Epilepsy Through Responsive Vagal Nerve Stimulation: A Three-Year Retrospective Study at the University of Texas Medical Branch, Galveston.
| Autor: | Villarreal J; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Valaparla VL; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Curtis K; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Thottempudi N; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Elrahi S; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Gil Guevara A; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Gogia B; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA., Sun R; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Masel T; Department of Neurology, University of Texas Medical Branch, Galveston, USA., Rai P; Department of Neurology, University of Texas Medical Branch, Galveston, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2021 Oct 12; Vol. 13 (10), pp. e18698. Date of Electronic Publication: 2021 Oct 12 (Print Publication: 2021). |
| DOI: | 10.7759/cureus.18698 |
| Abstrakt: | Background: Vagus nerve stimulation (VNS) functions through neuromodulatory mechanisms to provide quality of life improvements to those with drug-resistant epilepsy. Responsive VNS (rVNS) generators are designed to further reduce seizure burden by detecting ictal tachycardia and aborting seizures soon after their onset. Methods: Electronic medical records were accessed from January 2015 to December 2018 to identify patients with epilepsy managed with rVNS generators. Data were collected on seizure burden before and after rVNS implantation. Seizure burden was compared using t-tests, and monthly seizure reductions were gauged with the McHugh scale. Twenty-seven individuals met inclusion criteria; 10 were eliminated due to prior VNS implantation or undocumented seizure frequencies. Results: The average seizure burden prior to rVNS implantation was 24.78 seizures/month. Following generator placement, the mean seizure frequencies at three months, six months, 12 months, and 18 months were 6.81, 16.57, 5.65, and 5.78 seizures/month, respectively. However, despite documented reductions in the average monthly seizure frequency, we found no statistically significant differences in seizure frequency relative to baseline. Conclusion: While many participants showed individual reductions in seizure burden, this study was unable to definitively conclude that rVNS therapy leads to statistically significant reduction in seizure burden. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Villarreal et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|